Pharmacogenetics - Pharmacogenomics, what is the difference?;Pharmacogénétique - Pharmacogénomie, quelle est la différence?

Oncologie

Volumn 7, Issue 1, 2005, Pages 4-5

  Milano, G ^a   Robert, J ^b  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEFITINIB; IRINOTECAN; TRASTUZUMAB;

CANCER GENETICS; CHROMOSOME 18; COLORECTAL CANCER; DRUG INDUCED DISEASE; EDITORIAL; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 17844398963     PISSN: 12923818     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10269-005-0143-y     Document Type: Editorial

References (5)

1. Alaoui-Jamali MA, Dupre I, Qiang H (2004) Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. Drug Resist Updat 7: 245-55
2. Lynch TJ, Bell DW, Sordella R, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-39
3. Marsh S, Kwok P, McLeod HL (2002) SNP databases and pharmacogenetics: great start, but a long way to go. Hum Mutat 20: 174-9
4. Sachidanandam R, Weissman D, Schmidt SC, et al. (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409: 928-33
5. Uchida K, Hayashi K, Kawakami K, et al. (2004) Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 10: 433-9